Our study identified SREBF2 as a novel prognostic biomarker in CN-AML. Through gene enrichment and microRNA network analysis, SREBF2 interactions with genomic/transcriptomic elements were found to drive CN-AML pathogenesis, providing clinical insights for treatment strategies.
No takes yet. Share an insight, caveat, or question.
Shan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: